Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 11:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 8,261 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Risk Clear all
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression

NCT05797610
View directory record Official record
Conditions
Primary IgA Nephropathy
Interventions
Sefaxersen (RO7434656), Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
459 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
20
States / cities
Birmingham, Alabama • Glendale, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Oct 30, 2026, 11:00 PM EDT
Completed No phase listed Observational

Leveraging ctDNA Analysis to Improve Early Detection of Cancer Recurrence in the High-Risk Melanoma Setting

NCT05079113
View directory record Official record
Conditions
Stage III Melanoma, Stage IV Cutaneous Melanoma
Interventions
Not listed
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Oct 30, 2026, 11:00 PM EDT
Completed No phase listed Observational

SAPPHIRE Worldwide: Stenting and Angioplasty With Protection in Patients At High-Risk for Endarterectomy

NCT00403078
View directory record Official record
Conditions
Carotid Artery Disease
Interventions
Not listed
Lead sponsor
Cordis US Corp.
Industry
Eligibility
18 Years and older
Enrollment
21,008 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
5
States / cities
Newark, Delaware • West Des Moines, Iowa • Lincoln, Nebraska + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Oct 30, 2026, 11:00 PM EDT
Recruiting No phase listed Observational

The Synergistic Effects of Menopause and HIV on Cardiovascular Disease Risk in Women

NCT07284082
View directory record Official record
Conditions
HIV, Menopause, Cardiovascular (CV) Risk, Carotid Arteriosclerosis, Body Composition
Interventions
Whole body MRI
Diagnostic Test
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 30, 2026, 11:00 PM EDT
Recruiting Phase 2 Interventional

Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

NCT02559778
View directory record Official record
Conditions
Neuroblastoma
Interventions
Ceritinib, dasatinib, sorafenib, vorinostat, DFMO
Drug
Lead sponsor
Giselle Sholler
Other
Eligibility
Up to 22 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2035
U.S. locations
24
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Oakland, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 30, 2026, 11:00 PM EDT
Completed Not applicable Interventional Results available

Protected Carotid Artery Stenting in Subjects at High Risk for Carotid Endarterectomy (CEA) (PROTECT)

NCT00402740
View directory record Official record
Conditions
Carotid Artery Disease
Interventions
Xact Stent with either Emboshield Pro (Gen 5) or Emboshield (Gen 3)
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
38
States / cities
Fremont, California • Mountain View, California • Newport Beach, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2012 · Synced Oct 30, 2026, 11:00 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Genotypic and Phenotypic Correlates of Resistance to Aspirin

NCT01361620
View directory record Official record
Conditions
Platelet Dysfunction Due to Aspirin
Interventions
aspirin
Drug
Lead sponsor
George Washington University
Other
Eligibility
40 Years to 80 Years
Enrollment
190 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 16, 2013 · Synced Oct 30, 2026, 11:00 PM EDT
Completed No phase listed Observational

Hepatitis C Screening Alerts

NCT05710120
View directory record Official record
Conditions
Hepatitis C
Interventions
Hepatitis C Screening Alerts in CHORUS™, Standard of Care
Other
Lead sponsor
Epividian
Industry
Eligibility
18 Years and older
Enrollment
125,706 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 16, 2024 · Synced Oct 30, 2026, 11:00 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies

NCT05327023
View directory record Official record
Conditions
Hematologic Neoplasms
Interventions
donor lymphocyte infusion, Cyclophosphamide, Busulfan, Mycophenolate mofetil, Fludarabine, Sirolimus
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years to 120 Years
Enrollment
430 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 30, 2026, 11:00 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Project UNITY - HIV Risk Reduction and Vaccine Education Interventions

NCT00150098
View directory record Official record
Conditions
HIV Infections, Hepatitis B
Interventions
Enhanced HIV risk reduction and HIV vaccine education
Behavioral
Lead sponsor
New York Blood Center
Other
Eligibility
18 Years and older · Female only
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
2
States / cities
New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 8, 2014 · Synced Oct 30, 2026, 11:00 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Cardiorenal Protective Diet

NCT04117204
View directory record Official record
Conditions
Chronic Kidney Diseases, Cardiovascular Diseases, Hypertension
Interventions
Fruits and Vegetables
Other
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 29, 2021 · Synced Oct 30, 2026, 11:00 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Role of Sympathetic Overactivity and Angiotensin II in PTSD and CV

NCT02560805
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic
Interventions
Microneurography, Combat virtual reality video clip, Handgrip Exercise, Cold Pressor Test (CPT), Sodium Nitroprusside (SNP), Phenylephrine, Losartan, Atenolol, Transcutaneous Vagal Nerve Stimulation (tVNS), Sham Transcutaneous Vagal Nerve Stimulation (tVNS)
Procedure · Behavioral · Drug + 1 more
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2027
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 30, 2026, 11:00 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

HIV Prevention With Adolescents: Neurocognitive Deficits and Treatment Response

NCT01169922
View directory record Official record
Conditions
Risk Reduction Behavior, Sexual Behavior, Health Behavior, Drinking Behavior, Adolescent Behavior
Interventions
SEXUAL RISK REDUCTION + ALCOHOL RISK REDUCTION, INFORMATION-ONLY SEXUAL RISK REDUCTION
Behavioral
Lead sponsor
University of New Mexico
Other
Eligibility
14 Years to 18 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
4
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jan 10, 2024 · Synced Oct 30, 2026, 11:00 PM EDT
Completed No phase listed Observational

Neutrophil Gelatinase-associated Lipcalin(NGAL): A Novel Blood Marker for Determining the Risk of Developing Contrast-Induced Nephopathy

NCT00693329
View directory record Official record
Conditions
Cardiovascular Surgery With Coronary Angiography
Interventions
Not listed
Lead sponsor
Abbott RDx Cardiometabolic
Other
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
3
States / cities
Petoskey, Michigan • Providence, Michigan • Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 18, 2009 · Synced Oct 30, 2026, 11:00 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Risk Evaluation and Education for Alzheimer's Disease - the Study of Communicating Amyloid Neuroimaging (REVEAL-SCAN)

NCT02959489
View directory record Official record
Conditions
Alzheimer Disease, Amyloid Beta-Peptides, Risk Assessment, Education, Neuropsychological Tests, Neuroimaging
Interventions
Alzheimer's Disease Risk Disclosure, Amyloid Brain Imaging and Alzheimer's Disease Risk Disclosure
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
65 Years to 80 Years
Enrollment
315 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
4
States / cities
Boston, Massachusetts • Ann Arbor, Michigan • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Oct 30, 2026, 11:00 PM EDT
Completed Not applicable Interventional

Complex And Simple Appendicitis: REstrictive or Liberal Post-operative Antibiotic eXposure (CASA RELAX) - Atrium Health

NCT05746520
View directory record Official record
Conditions
Appendicitis Surgery
Interventions
Antibiotic
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
268 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Oct 30, 2026, 11:00 PM EDT
Completed Not applicable Interventional

Daily Meditation Program in Women Admitted to the Antepartum Unit

NCT03737279
View directory record Official record
Conditions
Pregnancy, High Risk, Pregnancy Related
Interventions
Meditation, Routine Care
Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older · Female only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Oct 30, 2026, 11:00 PM EDT
Completed Not applicable Interventional

Culturally Tailoring a Stroke Intervention in Community Senior Centers

NCT02181062
View directory record Official record
Conditions
Hypertension, Stroke, Sedentary Lifestyle, Aged, Minority Groups
Interventions
Walking Intervention
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
60 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
4
States / cities
Los Angeles, California • Montebello, California • Watts, California
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Oct 30, 2026, 11:00 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Rilematovir (JNJ-53718678) in Adult Outpatients With Respiratory Syncytial Virus (RSV) Infection

NCT04978337
View directory record Official record
Conditions
Respiratory Syncytial Virus
Interventions
Rilematovir, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 85 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
35
States / cities
Birmingham, Alabama • Tempe, Arizona • Bakersfield, California + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Oct 30, 2026, 11:00 PM EDT
Completed Phase 2 Interventional Results available

Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma

NCT00793572
View directory record Official record
Conditions
Refractory Plasma Cell Myeloma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Bortezomib, Cyclosporine, Fludarabine Phosphate, Laboratory Biomarker Analysis, Melphalan, Mycophenolate Mofetil, Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation, Syngeneic Bone Marrow Transplantation, Total-Body Irradiation
Procedure · Drug · Other + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 22, 2020 · Synced Oct 30, 2026, 11:00 PM EDT
Completed Not applicable Interventional Results available

Improving Control and Reducing the Risk of Hypoglycemic Episodes in Type 1 Diabetes

NCT00315939
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Integrated Biobehavioral Monitoring & Feedback - 1 (IBMF-1), Integrated Biobehavioral Monitoring & Feedback - 2 (IBMF-2)
Device
Lead sponsor
Boris Kovatchev, PhD
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 18, 2014 · Synced Oct 30, 2026, 11:00 PM EDT
Recruiting Phase 2 Interventional

Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer

NCT07250477
View directory record Official record
Conditions
Non-small Cell Lung Cancer Stage IIIC, Non-small Cell Lung Cancer Stage IV, Non Small Cell Lung Cancer, Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Unresectable
Interventions
Systemic (ICI)-based therapy informed by the PROphet CB assay and the CARG-TT assessment., Standard of Care
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2036
U.S. locations
4
States / cities
Chico, California • Marysville, California • Sacramento, California + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 30, 2026, 11:00 PM EDT
Completed Phase 1 Interventional

Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies

NCT00477035
View directory record Official record
Conditions
Leukemia, Multiple Myeloma
Interventions
CIK cells, etoposide, bcnu, cyclophosphamide, gemcitabine, vinorelbine, melphalan
Drug
Lead sponsor
Sally Arai
Other
Eligibility
18 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 30, 2026, 11:00 PM EDT
Withdrawn Phase 4 Interventional

Belatacept in Kidney Transplantation of Moderately Sensitized Patients

NCT02130817
View directory record Official record
Conditions
End Stage Renal Disease, Antibody Mediated Rejection
Interventions
Belatacept, Tacrolimus withdrawal, Plasmapheresis/Intravenous Immunoglobulin G, Thymoglobulin (ATG), Myfortic, Steroids
Drug · Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 17, 2018 · Synced Oct 30, 2026, 11:00 PM EDT